Ticker League

Total Liabilities for Vertex Pharmaceuticals (VRTX)

As of · Reported

Metric

Latest period

$7.12B

YoY change

+22.1%

5Y CAGR

+19.5%

Peak year (2025)

$7.48B

Total Liabilities history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: $7.48B

Total Liabilities growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: +22.1%

Total Liabilities history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

  • 2025$7.48B+22.1%
  • 2024$6.12B+18.9%
  • 2023$5.15B+21.5%
  • 2022$4.24B+27.2%
  • 2021$3.33B+8.7%
  • 2020$3.06B+37.2%
  • 2019$2.23B+23.3%
  • 2018$1.81B+20.4%
  • 2017$1.50B-3.5%
  • 2016$1.56B+10.9%
  • 2015$1.40B+13.4%
  • 2014$1.24B+28.7%
  • 2013$962.64M-38.4%
  • 2012$1.56B+22.5%
  • 2011$1.28B+4.4%
  • 2010$1.22B+42.2%
  • 2009$859.14M+15.8%
  • 2008$741.61M+124.6%
  • 2007$330.18M-20.6%
  • 2006$415.64M+34.2%
  • 2005$309.82M-39.3%
  • 2004$510.01M-4.1%
  • 2003$531.57M+21.6%
  • 2002$437.14M-2.8%
  • 2001$449.78M+5.3%
  • 2000$427.13M+1740.2%
  • 1999$23.21M+15.5%
  • 1998$20.10M+2.6%
  • 1997$19.60M+54.3%
  • 1996$12.70M-7.3%
  • 1995$13.70M+28.0%
  • 1994$10.70M-7.0%
  • 1993$11.50M+62.0%
  • 1992$7.10M+44.9%
  • 1991$4.90M+22.5%
  • 1990$4.00M—

Total Liabilities values are taken from Vertex Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Total Liabilities at Vertex Pharmaceuticals (VRTX)

According to Vertex Pharmaceuticals's latest reported financial statements, the company's latest reported total liabilities is $7.12B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

Vertex Pharmaceuticals (VRTX) most recent annual total liabilities stands at $7.48B (2025) – grew 22.1% year-over-year.

Through 2020–2025 (5 years), Vertex Pharmaceuticals total liabilities delivered a +19.5% annualised rate; with mixed annual results across the window.

Across the available history, total liabilities reached its high of $7.48B in 2025 and its low of $4.00M in 1990.

Vertex Pharmaceuticals Total Liabilities by Year

Vertex Pharmaceuticals Total Liabilities 2025: $7.48B

2025's total liabilities for Vertex Pharmaceuticals came in at $7.48B, grew 22.1% from 2024. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals Total Liabilities 2024: $6.12B

Vertex Pharmaceuticals posted total liabilities of $6.12B in 2024, grew 18.9% from 2023.

Vertex Pharmaceuticals Total Liabilities 2023: $5.15B

In 2023, Vertex Pharmaceuticals reported total liabilities of $5.15B, grew 21.5% from 2022.

Vertex Pharmaceuticals Total Liabilities 2022: $4.24B

Vertex Pharmaceuticals total liabilities in 2022 was $4.24B, grew 27.2% from 2021.

Vertex Pharmaceuticals Total Liabilities 2021: $3.33B

Vertex Pharmaceuticals total liabilities in 2021 was $3.33B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by Total Liabilities

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest total liabilities

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation